These are top 10 stocks traded on the Robinhood UK platform in July
On Tuesday, JMP Securities maintained a positive stance on Cidara Therapeutics (NASDAQ:CDTX), reaffirming a Market Outperform rating and a $47.00 price target, well above the current trading price of $24.28. According to InvestingPro data, the stock appears overvalued at current levels, despite analyst targets ranging from $35 to $50. The endorsement comes as the biotechnology company, which maintains a healthy balance sheet with more cash than debt and a strong current ratio of 3.87, anticipates results from its NAVIGATE Phase 2b trial for CD388, a novel drug aimed at preventing influenza.
The NAVIGATE trial is evaluating CD388, a non-vaccine, drug-Fc-conjugate designed to offer a new approach to flu prevention. The trial’s database has been locked, and a readout is expected in about a month. JMP Securities expressed confidence in the outcome of the trial and the potential impact of CD388 on flu prevention. InvestingPro subscribers can access 11 additional key insights about Cidara, including detailed analysis of its cash burn rate and profitability metrics, crucial factors for biotechnology investors.
Cidara recently held an R&D day to discuss the revised statistical plan for the NAVIGATE trial. During this event, management outlined the Phase 3 plans, including timelines for the trial and strategies for commercializing CD388 for use in high-risk populations.
Key opinion leaders (KOLs) who spoke at the R&D day expressed enthusiasm for CD388’s unique profile. They highlighted its high potency against various influenza strains, which is expected to last the entire flu season. Additionally, they noted CD388’s high barrier to resistance and the capability for it to be rapidly manufactured, which could be crucial in responding to flu outbreaks.
The analyst at JMP Securities, Roy Buchanan, commented on the potential of CD388, stating, "We remain confident in a positive outcome for the trial in approximately one month, and to this highly differentiated option making a difference for flu prevention; we reiterate our Market Outperform rating and risk-adjusted, DCF-derived $47 price target on Cidara Therapeutics."
Investors and industry observers will be closely watching for the trial results, which could significantly influence Cidara Therapeutics’ trajectory and the broader market for influenza prevention solutions. The stock has shown significant volatility, with a -9.74% return over the past week but an impressive +102% return over the last year. For comprehensive analysis and detailed financial metrics, including exclusive Fair Value calculations and health scores, check out the full research report available on InvestingPro.
In other recent news, Cidara Therapeutics reported its first-quarter financial results, highlighting lower-than-expected expenses and a strong cash position of $174 million. The company is advancing its influenza prevention drug, CD388, through a Phase 2b trial with top-line data expected in late June. Analysts from JMP Securities have raised Cidara’s stock target to $47, maintaining an outperform rating, based on anticipated promising trial results. Sadara Therapeutics, meanwhile, is also focusing on CD388, having completed dosing of 5,041 subjects in its Phase 2b Navigate study, with results expected in June 2025. A Phase 3 study is planned for high-risk populations in Spring 2026. Sadara is exploring potential collaboration with BARDA for H5N1 prevention, highlighting the drug’s potential market opportunities. Both companies are preparing for a virtual Research and Development day on May 22, which will provide further updates on their clinical trials and commercial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.